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Molecular imaging using PET/CT or PET/MRI has evolved from an experimental imaging
modality at its inception in 1972 to an integral component of diagnostic procedures in
oncology, and, to lesser extent, in cardiology and neurology, by successfully offering invivo imaging and quantitation of key pathophysiological targets or molecular signatures,
such as glucose metabolism in cancerous disease. Apart from metabolism probes, novel
radiolabeled peptide and antibody PET tracers, including radiolabeled monoclonal
antibodies (mAbs) have entered the clinical arena, providing the in-vivo capability to
collect target-speciﬁc quantitative in-vivo data on cellular and molecular
pathomechanisms on a whole-body scale, and eventually, extract imaging biomarkers
possibly serving as prognostic indicators. The success of molecular imaging in mapping
disease severity on a whole-body scale, and directing targeted therapies in oncology
possibly could translate to the management of Coronavirus Disease 2019 (COVID-19), by
identifying, localizing, and quantifying involvement of different immune mediated
responses to the infection with SARS-COV2 during the course of acute infection and
possible, chronic courses with long-term effects on speciﬁc organs. The authors
summarize current knowledge for medical imaging in COVID-19 in general with a focus
on molecular imaging technology and provide a perspective for immunologists interested
in molecular imaging research using validated and immediately available molecular
probes, as well as possible future targets, highlighting key targets for tailored treatment
approaches as brought up by key opinion leaders.
Keywords: SARS-CoV-2, CXCR4, P2X7 (purino) receptor, ACE-2-receptor, COX-2, cytokine storm, molecular
imaging, COVID-19
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possible the systemic and potentially local inﬂammatory
responses induced by SARS- CoV-2 and how these pathways
are modulated by the different therapies currently used as
standard of care or in clinical trials, [ … ] clinical centers that
have the means to perform deep-monitoring studies now have
the responsibility to conduct such studies and to share their
strategies and results with the scientiﬁc community”. In this
article, the authors present their position on how molecular
imaging for COVID-19 ﬁts to this appeal and why it should
widely be used by immunologists.

INTRODUCTION
In response to the current pandemic of Coronavirus Disease 2019,
medical imaging research ﬁrst focused on procedure and safety
guidelines and the integration of medical imaging into the
diagnostic workﬂow for COVID-19 (1–4). In the meantime, the
spectrum of associated symptoms attributed to the disease has
become larger, clearly exceeding the notion of it being primarily a
severe pneumonia with fever, cough and dyspnea, thus warranting
to extend medical imaging to provide information not only on
pulmonary condition. Early observational studies reported older
age and the presence of comorbidities as risk factors for increased
disease severity. With increasing incidence of COVID-19, an
increasing number of severe courses of disease have been
reported in younger patients with no pre-existing, medical
conditions (5). Acute respiratory distress syndrome (ARDS) is a
common complication of severe viral pneumonia, and is reported
to occur in 15.6% of patients with severe COVID-19
pneumonia (6).
Accumulating evidence suggests that some of the detrimental
effects seen in patients with COVID-19 is attributed to an overly
host antiviral defense as described earlier in severe acute
respiratory syndrome (SARS), leading to hyperinﬂammatory
reactions (7) or cytokine storm syndrome, sometimes
culminating to affect the central nervous system (CNS) (8),
and often associated with increased serum levels of several
inﬂammatory cytokines and chemokines (9).
There is also an increasing number of COVID-19 associated
cases with systemic or localized inﬂammatory disease, such as
vasculitis (10), endothelial cell dysfunction (11), Kawasaki-like
disease in the young (12), nephritis (13), Guillain–Barré syndrome (14) or inﬂammatory bowel disease (15), with no
indication of lab ﬁndings, clinical signs, or symptoms
predictive of their appearance. The factors that ultimately
trigger severe illness in individuals infected with SARS-CoV2 are not completely understood and as in other systemic
inﬂammatory conditions, the development of severe disease
may be preceded by signs of locally contained inﬂammatory
reactions, occult to clinical observation, but possibly visible by
molecular imaging.
In a recent comment, Merad et al. appealed “to start
measuring longitudinally and with as much granularity as

GENERAL CLINICAL CONTRIBUTION OF
MEDICAL IMAGING TO LONGITUDINALLY
INVESTIGATE COVID-19
Medical imaging, in certain, clinical settings being on the
frontline of diagnostics in COVID-19 (4, 16, 17), is able to
provide objective, longitudinal measures of both systemic and
local disease involvement. During the unfolding of the
pandemic, chest-CT scanning has grown into a clinically
well-established procedure in the early diagnosis of
COVID-19 in patients with symptoms ranging from none to
very severe (3). Depending on the diagnostic workﬂow of an
individual institution, CT may well be a very initial diagnostic
procedure, in some situations even preceding PCR diagnostics
(18, 19), and accordingly, CT has been integrated into
various diagnostic algorithms for COVID-19 (4, 20). Recent
progress in clinical applications of artiﬁcial intelligence
(AI) in COVID-19 (21–23) has led to approval of ﬁrst
clinical products for AI-based, automated detection of
COVID-19 related changes in chest-CT, integrating
differentiation criteria not always obvious to the eye of less
experienced observers.
By current recommendations of the American and
European Radiological Societies, computed tomography (CT)
of the chest is indicated in COVID-19 patients with respiratory
symptoms and may be helpful in patients with milder
symptoms but co-morbidities, with repeat CTs indicated in
cases with suspected complications (e.g. superinfection,
pulmonary embolism) (24).
With systematic data just being built up, however, it still
remains ﬂuent, to which extent imaging studies add to the
clinical management of COVID-19 and its complications.
Current notion includes that speciﬁc exams might add to
clinical understanding in selected cases as in suspected
myositis, perimyocarditis or possible CNS involvement
(25, 26).
As a subgroup of COVID-19 patients that seems to do well
after getting out of the intensive care unit, dies of acute
respiratory syndrome just several days later, without clinical
signs indicating their imminent deterioration, systematic
whole-body imaging data on the inﬂammatory burden
during the course of disease, including a refractory phase
after intensive care, could be a potential life-saver for
individual patients.

Abbreviations: COVID-19, Coronavirus disease 2019; SARS-CoV-2, Severe acute
respiratory syndrome coronavirus 2; ARDS, Acute respiratory distress syndrome;
CT, Computed tomography; AI, Artiﬁcial intelligence; FDG, Fluordeoxyglucose;
PET, Positron emission tomography; MRI, Magnetic resonance imaging; CNS,
Central nervous system; RIG-I, Cytosolic retinoic acid-inducible gene I; RLRs,
RIG-I like receptors; TLRs, Toll-like receptors; IFNs, Interferons; CXCR4, C-X-C
Motif chemokine receptor 4, also: chemokine-receptor type 4; ATP,
Adenosinetriphosphate; P2X7, ATP-purinergic receptor P2X7, also: P2X
purinoceptor 7; FAP, Fibroblast activation protein; ACE-2, Angiotensinconverting enzyme 2; ATR1, Angiotensin-II-receptor type 1; COX-2,
Cyclooxigenase-2; NSAIDs, Non-steroidal anti-inﬂammatory drugs; COX-1,
Cyclooxigenase-1; CD-8+, Cluster of differentiation 8 antigen positive; NK-cells,
Natural killer cells; uEXPLORER, Ultra-High-Resolution total-body digital PET/
CT with 194 cm axial ﬁeld of view; UCDavis, University California, Davis;
PennPET, Pennsylvania University whole-body digital PET/CT with 64 cm axial
ﬁeld of view; WHO, World Health Organization.
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fever without origin, are now established indications for
FDG-PET/CT (29, 31–33). More recently, hybrid molecular
imaging using FDG-PET/MRI has attracted attention for
combining the superb imaging characteristics of both, MRI and
PET in a simultaneous exam, deﬁning a new imaging gold
standard (34) with increasing sensitivity and speciﬁcity in soft
tissue pathologies.
Early case series in COVID-19 patients indicate that wholebody FDG-PET/CT is highly sensitive for detection and
quantiﬁcation of inﬂammatory pulmonary involvement (35), as
well as extrapulmonary inﬂammatory disease, e.g. in lymph
nodes, intestine or implant sites of interventional cardiac
devices (36–40). Given the high diagnostic accuracy for
FDG-PET/CT in substantiating localized inﬂammation on a
whole-body level even in early stages of inﬂammatory disease
(29), and the broad availability of the modality in North and
Latin America, Europe, Asia and Oceania with a heterogenous
availability in Africa (41), it would be an easy-to-accomplish task
to conduct prospective, longitudinal, multicentric studies in
COVID-19 patients at different stages of severity, to a) identify
extrapulmonary inﬂammatory disease manifestations and b)
search for possible imaging biomarkers of later severe and
potentially life-threatening inﬂammatory reactions, thus
possibly identifying individuals in need of speciﬁc antiinﬂammatory treatment.
While FDG is the most frequently used PET radiopharmaceutical
to date, the intrinsic ability of PET to provide tailored targeted
molecular imaging has drawn interest from a growing body of
medical specialties, including immunology, where radiolabeled
monoclonal antibodies (mAbs) and intermediary compounds of
the immunological response have been successfully introduced and
are summarized under the term Immuno-PET (42–46). Close
collaboration between radiopharmacists, radiochemists, clinicians,
and nuclear medicine specialists has increased the number and
species of radiotracers, with an exquisite pool of established and
conceptionalized radiolabeled biomarkers bearing the unique
potential of providing primary quantitative data on cellular or
even molecular level on a whole-body scale, allowing for a
pictorial whole-body cartography of the process under
investigation. As current PET imaging has almost completely
turned into hybrid imaging, either diagnostic CT or MRI will be
acquired along with the PET investigation and thus offers an
unparalleled view into the pathophysiological changes associated
with an individual course of disease.
In comparison to standard immunological testing, which also
provides longitudinal information of inﬂammatory disease in
COVID-19, whole-body imaging adds the anatomical
localization of the pathophysiology, which may prove clinically
relevant for the assessment, targeted treatment and follow-up of
organ-speciﬁc disease such as myocarditis, pericarditis,
inﬂammatory bowel disease, pancreatitis and chronic
inﬂammatory disease or vascular inﬂammation (47).
As each diagnostic receptor binding site also inherently
represents a possible target site for newly developed or
repurposed therapeutic agents, simultaneous therapeutic
application during an imaging study poses an intrinsic

RATIONALE FOR AND POTENTIAL
OF SYSTEMATIC CLINICAL STUDIES
ON TARGETED MOLECULAR IMAGING
USING POSITRON EMISSION
TOMOGRAPHY IN COVID-19
The scientiﬁc response to COVID-19 has been extraordinary,
with a plethora of studies designed to rapidly unravel the
pathogenesis of COVID-19 and potential therapeutic strategies,
often posted in preprint servers to speed up access to the
scientiﬁc community. While preclinical in-vitro and in-vivo
data has rapidly accumulated and undoubtedly plays an
important role in anticipation and design of clinical studies
and future, prospective clinical trials, the need for human
in-vivo-evidence for the applicability of proposed therapeutic
strategies is still unmet and evolving.
MRI and PET/CT are the two key imaging modalities that
have been investigated extensively for providing non-invasive
information on localization and extent of inﬂammatory disease
and disease of autoimmune origin (27, 28), with MRI being the
most frequently used modality and whole-body PET/CT yielding
the highest sensitivity and speciﬁcity even for clinically occult
disease [for review (29)].
The exquisite sensitivity of PET imaging is based on the tracer
principle, where radiopharmaceuticals designed to speciﬁcally
aim a physiological target are introduced into the patient and are
subsequently detected by quantitative counting of positron
emissions originated by their radioligand, allowing for
localization and visualization by computed reconstruction of
their spatial distribution. PET thus allows for observing and
quantifying molecular signatures as targeted by the
radiopharmaceutical, non-invasively, in vivo, with a resolution
in the space domain in the range of millimeters and in the time
domain in the range of seconds to a couple of days or even weeks,
depending on the speciﬁc half-life of the radionuclide coupled to
the carrier molecule.
As deﬁned by the tracer principle, the amount of carriertarget-complex injected is always below the threshold of a
pharmacological effect, with a sensitivity of the method
allowing for quantitation of picomolar to nanomolar
concentrations (30). The technological evolution of combining
advanced PET detectors and CT into one single hybrid scanner
has led to scanning times down from an initial hour-long
procedure to whole-body scans feasible in a couple of seconds,
having allowed a widespread clinical adoption of PET for
oncologic indications and facilitating imaging procedures even
in the severely ill. The most frequently used PET
radiopharmaceutical to date is 18-F-Fluorodeoxyglucose
(FDG), targeting the glucose transporter 1 (GLUT-1), which is
overexpressed in many malignant cells, but also in cells
responsible for inﬂammatory response.
The increased availability of the technology over the past two
and a half decades of its clinical implementation has also
broadened its clinical applications, and imaging of inﬂammatory
disease, e.g. in large vessel vasculitis, autoimmune encephalitis or
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displacement challenge for its diagnostic twin, with dynamic
imaging allowing for a quantitative, summative monitoring of
treatment effect based on cellular level.
The whole potential of PET/CT or PET/MRI, however, can
only unfold in an interdisciplinary collaboration of the related
disciplines of immunology, virology, clinical medical specialties,
pathology and nuclear medicine, and requires a dedicated effort
to establish controlled clinical study protocols using a wise
selection of rapidly available radiopharmaceuticals (48). Such
an effort would allow the medical specialties involved to make
best use of the full potential of molecular imaging to identify key
pathogenic mechanisms, to quantify disease process and to
predict disease outcome, thus facilitating evidence-based
medicine in COVID-19.

ATP-Purinergic Receptor P2X7 Pathway
Another potent activator of the innate immune system related to
antiviral response that recently has come into focus, is the
purinergic receptor P2X7 (56–58), which is mainly expressed in
inﬂammatory and immune-related myeloid cells – macrophages
and microglia. P2X7 receptors are potent stimulants of
inﬂammation, mediating the activation of the NLRP3
inﬂammasome, as well as cytokine and chemokine release, thus
forming a natural target for anti-inﬂammatory therapy. A number
of radiopharmaceuticals selective to the P2X7 receptor have been
developed, are meanwhile well established, and have already been
put into clinical practice (59). While initially designed to quantify
neuroinﬂammation, they can easily be repurposed for imaging and
quantifying localized inﬂammation at a whole-body scale. As there
are also potential P2X7-inhibitors at receptor level, showing antiinﬂammatory effects in animal models (60), P2X7-receptor imaging
may here form the rationale for directing and monitoring antiinﬂammatory therapy in case of regional or systemic involvement in
COVID-19.

CURRENTLY ESTABLISHED,
MOLECULAR TARGETS POSSIBLY
SUITABLE FOR COVID-19
Chemokines and Chemokine Receptors

Postinﬂammatory Fibrosis

An excessive inﬂammatory response to SARS-CoV-2 at a given
timepoint of the disease, often in its later stages, is thought to be a
major cause of disease severity and death in patients with
COVID-19 and is associated with high levels of circulating
cytokines, profound lymphopenia and substantial mononuclear
cell inﬁltration in the lungs, heart, spleen lymph nodes and
kidneys, as observed in post-mortem analysis (49).
In the absence of preexisting antibodies to a viral infection, innate
immune sensing triggers a pathway of speciﬁc immune responses as
a ﬁrst line of antiviral defense. While data on the speciﬁc innate
immune response to SARS-CoV-2 is still limited, a certain analogy to
the well-studied immune responses to other coronaviruses may be
expected, where cytosolic retinoic acid-inducible gene I (RIG-I) like
receptors (RLRs) and extracellular and endosomal toll-like receptors
(TLRs) trigger signaling cascades resulting in the secretion of
cytokines (49) and have shown to sit at the crossroads of multiple
inﬂammatory pathways including neuroinﬂammatory disease (50).
Early antiviral defense is mediated by type I/III interferons (IFNs),
followed by inﬂammatory cytokines and chemokines. Immune cell
proﬁling of COVID-19 patients in the recovery stage has shown high
expression levels of the chemokine receptor CXCR4 in
inﬂammatory monocytes, possibly indicative for fueling the
inﬂammation during SARS-CoV-2-infection (51). As targeting
CXCR4 has been subject to intensive studies due to involvement
of the chemokine axis in tumor progression (52, 53), suitable
radiopharmaceutical conjugates of CXCR4 as well as potent
CXCR4 antagonists have been developed and thoroughly
described (54, 55) and thus could be easily repurposed to
investigate the cytokine signaling pathway in COVID-19 and
monitor possible effects of targeted therapy with CXCR4
antagonists by quantifying the regional level of CXCR4 activity
over time. Unlike lab ﬁndings mainly reﬂecting systemic
inﬂammatory activity, molecular imaging has the potential to early
identify the involvement of speciﬁc organs and monitor their
response to therapy.

There is accumulating data that recovery after COVID-19 infection
can be associated with persistent organ damage induced by
postinﬂammatory ﬁbrosis (61), and early detection of prolonged
ﬁbroblast activation related to inﬂammation could warrant tailored
therapies directed at mitigation of ﬁbrosis and an underlying
inﬂammatory process. Molecular imaging here could play a
critical role for understanding the extent of systemic disease and,
by visualizing, help to direct therapy and follow up therapy
response. One out of a number of possible molecular targets that
have gained considerable interest most recently, are the integrins,
which derive their name from which derive their name from their
role of integrating the extracellular matrix with the insoluble cellular
cytoskeleton. The ﬁeld of integrin research was advanced
enormously by the detection of the crystal structure of the
extracellular domain of avb3 in 2001 (62). This structure shows
that the globular head of the integrin is made up of a seven-bladed
b-propeller contributed by the a-subunit and the A-domain from
the b-subunit together with an immunoglobulin fold, made up of
polypeptide sequences from either side of the b A-domain. The
integrin stalks are folded into three b-sandwich domains in the a
and four epidermal growth factor (EGF)-like repeats in the
b-subunit. The ligand-binding speciﬁcity of integrin molecules is
determined by the particular a–b combination and consequently
determines the adhesion speciﬁcity of different cell types. Recent
research has successfully led to radiolabeled avb6-binding peptides,
which are targeting an epithelium-speciﬁc cell surface receptor that
is low or undetectable in healthy adult epithelium but upregulated in
select injured tissues (63–65), where it has successfully been shown
by immunohistochemical analysis of biopsy specimens, that tissues
showing high uptake on 18F- avb6-BP PET/CT in patients with
cancer indeed correlated with high expression of integrin avb6 for
tissues (NCT03164486) (64). Following the call to repurpose well
characterized imaging biomarkers for COVID-19 research (66), the
same group recently proposed to extend the use of the
demonstrated integrin avb6 imaging agent 18F-avb6-BP to assess
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lung damage in patients after severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection in a ﬁrst-in-human study
(67). In their preliminary study, the authors were able to
demonstrate a correlation of integrin avb6-targeted 18F-avb6-BP
PET with lung damage identiﬁed by CT. The authors concluded invivo integrin imaging to be a promising strategy to detect and
monitor the development and progression of lung ﬁbrosis after
SARS-CoV-2 infection, with a better understanding of the nature of
the tissue remodeling and progression in recovering patients over
time being the key for developing therapeutic strategies to prevent
irrecoverably disease.
Another key protein for activation of the ﬁbroblast cascade,
leading to destructive organ ﬁbrosis, is the ﬁbroblast activation
protein FAP (68), which has been studied for almost three decades.
As it has gained special attention as a highly expressed marker in
the vast majority of epithelial tumors, considerable amount of
research has been put into developing FAP-radioligands, resulting
in a number of radiolabeled FAP-antagonists suitable for wholebody PET imaging (69). One of those radiolabeled imaging agents,
18-F-FAPI has just entered clinical oncologic imaging on the base
of large-scale clinical trials, with the potential of becoming the next
most used PET imaging agent besides FDG, as it has been shown
to prove diagnostic information for a multitude of different
tumor entities.
With novel FAP antagonists showing promising ﬁrst results
to mitigate FAP induced ﬁbrosis (70), the repurposing of FAPdirected radiopharmaceuticals currently under extensive
investigation for oncology may open up a new door in
directing protective or restorative therapy to treat COVID-19
associated sequelae.

Role of Cyclooxigenase-2 in COVID-19
Related Inﬂammatory Reaction
COX-2 is unexpressed under normal conditions in most cells,
and expression is stimulated via up-regulation of prostaglandins
during inﬂammation of various types. Non-steroidal antiinﬂammatory drugs (NSAIDs) inhibit prostaglandin
production, Cyclocoxigenase-1 (COX-1) and COX-2. NSAIDs
selective for inhibition of COX-2 are commonly prescribed for
the control of fever and other symptoms in COVID-19 and
recently have come under scrutiny for anecdotal reports of
worsening the course of disease. In the current discourse of
controversial concepts of biological plausibility that possibly
leads to contradictory concepts of recommendations (76),
quantitative imaging of COX-2-involvement using established
COX-2-inhibitory radiopharmaceuticals (77) would lead the way
to provide evidence for general therapeutic guidelines or could
even inform individualized future treatment options.

Cell Tracking of CD-8+ T-Lymphocytes
T-lymphocytes and natural killer (NK)-cells play critical roles in viral
clearance during respiratory infections. Recent reports of decreased
ratio of CD8+ T cells in COVID-19 patients may implicate a role of
CD8+ T cells in virus clearance (51), mostly at a later timepoint of the
disease. CD8+ T-lymphocytes are preferred immune cells in cancer
immunotherapy, and extensive research already has gone into PET
imaging of cytotoxic human T cells, recently resulting in ﬁrst-inhuman imaging studies of anti-CD-8 imaging in patients with solid
tumors (78). The application of novel radioligands with radioactive
half-time of more than 72 h allows for the concept of in-vivo cell
tracking of CD-8+ T-lymphocytes, which for clinical application in
solid malignancies currently is in a Phase-II clinical trial (79). In-vivo
cell tracking of CD-8+ T-lymphocytes would therefore be available
in dedicated research centers and could contribute to monitoring the
course of immune defense during COVID-19 infection and possibly,
response to convalescent plasma therapy (80) or early immunization
trials. They also could prove helpful in tracking a possible
involvement of aberrant activation of CD-8+ T-lymphocytes in
multi-organ damage including cardiac injury, which will be of
increasing clinical importance with a steadily rising number of
reports on multi-organ involvement in COVID-19.

ACE-2-Receptor and
ATR1-Receptor Imaging
Other, still more experimental radiopharmaceuticals which
would prove useful in COVID-19 infection focus on directly
targeting the entry receptor for SARS-CoV-2, the angiotensinconverting enzyme 2 (ACE-2)-receptor, involved in cellular
internalization of SARS-CoV-2 (71, 72) and, downstream, the
type 1 angiotensin-II-receptor ATR1 (e.g. KR31173). Numerous
reports have linked tissue speciﬁc ACE-2 expression to organ
injuries by ACE-2-mediated viral homing and attachment to
organ-speciﬁc cells, as well as to the role of ACE-2 bearing
macrophages potentially serving as trojan horse, triggering
pulmonal anchoring and migration out of the lung to other
tissues alike (73). Whole-body ACE-2-receptor imaging would
therefore provide a unique means to survey entry-points as well
as immunoreactivity during the course of COVID-19 infection.
Radiolabeling of ACE-2-receptor antagonists has been
achieved for receptor autoradiography protocols (74), and
could serve as starting point for a future PET tracer
development that would be able to provide quantitative data
on receptor based virus entry load in-vivo. Preclinical imaging of
ATR1 has also been successfully achieved using 11C- or 18Flabeled compounds and preclinically available receptor
antagonists (75), which could be used to better deﬁne and
verify a point of pharmaceutical intervention.
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DEPICTING EVENTS AT EARLIER TIME
POINTS OF COVID-19
Proinﬂammatory chemokine receptor 2+ (CCR2+) macrophages
are important mediators of inﬂammation during the early course of
COVID-19 and are therefore a potential target of interest for
quantitation of localized inﬂammation in the beginning of
infection with SARS-CoV-2. CCR2-binding peptides have been
labeled with 64Cu for use as PET radiotracer (64Cu-DOTA-ECL1i)
and have been successfully evaluated in a preclinical mouse model
of lung inﬂammation (81, 82). The very rapid blood clearance of
64
Cu-DOTA-ECL1i, however, may possibly limit its practical use in
human studies, and further research may be necessary to adapt this
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for derived decisions on treatment approaches. As controlled
studies on COVID-19 patients will have to be performed in an
interdisciplinary setting and precautions to comply with for
medical procedures in these patients are high, any imaging
study should be designed in a way to generate the most
comprehensible data possible. Nuclear medicine procedures
using PET/CT and PET/MR are elegantly combining imaging
data from two modalities in a single imaging session, thus
reducing the number of patient visits and contact time under
extensive precautions. Besides providing new pathophysiological
insights of immune response in COVID-19 using molecular
probes, any PET/CT or PET/MR performed in these patients
will also provide fully diagnostic CT or MRI exams at the same
time, thus being able to answer clinical questions in need, and
according to current evidence. Additionally, as PET/CT and
PET/MR by design are intended to cover a whole-body
imaging ﬁeld, nuclear medicine will be able to shed light on
the increasing number of extrapulmonary organ involvement
that we are just beginning to fully recognize. With the glucose
analog on FDG being the most available routine tracer for PET
imaging, an unspeciﬁc but highly sensitive probe for localized or
generalized inﬂammatory disease is readily and immediately
available, and given the improved sensitivity of the current
generation of PET/CT and PET/MRI scanners, these
procedures can be safely performed even in the youngest of
our patients and in the worst of their clinical conditions.
Tailored radiopharmaceuticals beyond FDG that already have
been established and thus can be made available with modest effort
will, on a short time-scale, allow to conduct controlled and
prospective studies of various levels on interaction of SARS-CoV2 related immunopathomechanisms, to better understand when
and where detrimental processes are being activated. This would
help to early diagnose critical organs at risk of inﬂammatory
destruction and to potentially guiding the observer on diseasedirected pharmacologic interventions according to receptor status,
biochemical status or receptor ligand status.
Institutions providing one of the most advanced whole-body PET
scanners like the uEXPLORER at UCDavis or the PennPET Explorer
might spearhead clinical studies by their unique capability offast and
comprehensive whole-body dynamic and quantitative imaging and
of whole-body acquisition times in the range of seconds. PET/MRI
using dedicated tracers could prove to be helpful in cases of occult
myositis, endocarditis, myocardial inﬂammation, or myopathy, as
well as CNS involvement. A pictorial review of selected, possible
imaging targets and their relation to current concepts of therapeutical
interventions is given in Figure 1.
And ﬁnally, if further, speciﬁc targets of interest are discovered by
clinicians, appropriate biochemical markers and radiopharmaceuticals
can be tailored to address the most imminent needs.
The examples on radiopharmaceuticals chosen here are not meant
to be comprehensive. They are meant to give a perspective and to
exemplify how certain steps of viral interaction within the human body
and its immune response can be quantitatively and longitudinally
assessed, potentially directly guiding speciﬁc treatment based on
evidence, using existing and well described radiopharmaceuticals that
are easily to be repurposed. The examples are also meant to stimulate

promising PET probe to clinical needs in imaging early course of
inﬂammatory disease in humans.
Additionally to CCR2+monocytes, according to, IL-6 could also
be a target for PET probes at earlier time points of COVID-19. There
is, however, currently no conceptualized radiotracer targeting IL-6,
warranting further radiopharmaceutical research to ﬁll this gap.

SUMMARY
Due to the still unfolding character of the COVID-19 pandemic,
only the lowest level of evidence for medical imaging (level V out
of ﬁve levels of evidence-based medicine criteria) is available, with
a consensus statement reached by a multidisciplinary expert panel
just recently jointly published by the American College of Chest
Physicians and the Radiological Society of North America and a
rapid advice guide published by the World Health Organization
(WHO) in June 2020. According to their statements, chest-CT is
regarded appropriate in patients with COVID-19 and worsening
respiratory status (83), and for symptomatic patients with
suspected COVID-19, when rt-PCR testing is not available or
delayed or when initial rt-PCR testing is negative, but a high
clinical suspicion of COVID-19 persists (84). With only limited
experience for other imaging modalities such as Ultrasound, MRI
and FDG-PET/CT, there are no evidence based criteria yet
allowing to recommend their use in COVID-19 on a routine base.
Molecular imaging, however, offers a potential clearly exceeding
the obvious primary clinical goal, to establish a correct diagnosis: it
offers tailored means to identify and quantify on cellular and
molecular levels important elements of the cascade of
immunological and immune-mediated events triggered by the
entrance of SARS-CoV-2 into the human body and to ultimately
predict at early timepoints the course of disease in an individual
patient, which would form the rationale for a patient-centric,
tailored therapeutic approach.
Limiting an early success of molecular imaging would be that
clinical manifestations of COVID-19 are complex and not all patients
are suffering the same symptoms—which would imply that clinicians
and immunologists should widely use molecular imaging for COVID19 and systematically investigate patients, deﬁning and using those
molecular targets that are most promising for understanding the
course of disease and tailoring timely therapy to prevent sequelae and
death from this still devastating disease, taking into account as much of
interdisciplinary collaboration as possible and necessary.
While costs may also be considered a limiting factor for wide
application of molecular imaging, cost calculations would have to
take into account the potential of costs saved by preventing more
severe courses of disease, chronic disease and possible early
death. Considering that molecular imaging has been shown to
be cost-effective in a variety of cancer conditions (85–87), it is
conceivable that this might equally be the case for COVID-19,
where life expectancy and life quality without the event of
infection would be unimpaired. Allocation of research funds
would thus follow the same principles as in cancer research.
Undoubtedly, there is an urgent need for higher level of
evidence for medical imaging in COVID-19 and, subsequently,
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FIGURE 1 | Pictorial review highlighting selected molecular imaging targets for pathophysiological features of coronavirus disease 2019 (COVID-19) and their relation
to current concepts of therapeutical interventions, based on a schematic representation of the reproduction cycle of SARS-CoV-2 at the alveolus–host cell interface.
Radiopharmaceuticals (red italic) are depicted at their speciﬁc binding sites: receptor antagonists binding to their respective receptors, integrin ligands and FAPIantagonists schematically binding to their respective target structures. Intracellular therapeutic interventions (green) and systemic interventions (red) are shown for
their possible downstream effects that will inﬂuence the dependent functional imaging principle. Each diagnostic receptor binding site also represents a possible
therapeutic target site, thus any therapeutic use of receptor antagonists intrinsically forms a displacement challenge for its diagnostic twin, allowing a direct
quantitation of localized therapeutic receptor binding.

follow-up will be key to identifying imaging biomarkers and
other predictive measures of prognostic signiﬁcance.

the scientiﬁc community’s potential to contribute to one of the
biggest challenges in modern medicine and to plan and conduct
multicentric trials and to share what it needs for making novel
radiopharmaceuticals accessible at an accelerated time scale.
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Molecular imaging repurposing molecular probes already
established in nuclear medicine have the immediate perspective
of facilitating evidence based medicine in COVID-19 by
providing in-vivo quantitative measures of molecular and
immunological mechanisms on a whole-body scale. To fulﬁll
this goal, immunologists and clinicians alike should widely use
molecular imaging as a longitudinal measure in future clinical
trials as well as in controlled patient cases. A prospective buildup of a longitudinal molecular imaging database for COVID-19,
including pathological ﬁndings, lab measures, and clinical
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55. Poty S, Dé sogère P, Nicholson K, Nigam S, Goze C, Boschetti F, et al. New
Imaging Agents Targeting Chemokine Receptor CXCR4 for PET/SPECT and
MRI. EJNMMI Phys (2014) 81. doi: 10.1186/2197-7364-1-s1-a81
56. Martı́nez-Banaclocha H, Pelegrı́n P. Detection of Inﬂammasome Activation
by P2X7 Purinoceptor Activation by Determining ASC Oligomerization. In: .
Methods in Molecular Biology. Humana, New York, NY. (2019) p. 335–43.
doi: 10.1007/978-1-4939-9717-6_25
57. Savio LEB, Mello P de A, da Silva CG, Coutinho-Silva R. The P2X7 Receptor
in Inﬂammatory Diseases: Angel or Demon? Front Pharmacol (2018) 9:52.
doi: 10.3389/fphar.2018.00052

Frontiers in Immunology | www.frontiersin.org

9

May 2021 | Volume 12 | Article 568959

Juengling et al.

Molecular Imaging for COVID-19

COVID-19: A Rapid Review (2020). Available at: https://apps.who.int/iris/
bitstream/handle/10665/332326/WHO-2019-nCoV-Clinical-Radiology_
imaging-Web_Annex_A-2020.1-eng.pdf (Accessed November 30, 2020).
85. Schnitzer ML, Froelich MF, Gassert FG, Huber T, Gresser E, Schwarze V, et al.
Follow-Up 18F-FDG PET/CT Versus Contrast-Enhanced CT After Ablation
of Liver Metastases of Colorectal Carcinoma—a Cost-Effectiveness Analysis.
Cancers (Basel) (2020) 12:1–14. doi: 10.3390/cancers12092432
86. Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, et al. Use
of 18F-FDG PET/CT as an Initial Staging Procedure for Stage Ii-III Breast
Cancer: A Multicenter Value Analysis. JNCCN J Natl Compr Cancer Netw
(2020) 18:1510–7. doi: 10.6004/JNCCN.2020.7598
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